Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

NCT05438498 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

550

Enrollment

INDUSTRY

Sponsor class

Stopped FDA withdrew EUA for AZD7442

Conditions

SARS-CoV-2 Infection

Interventions

DRUG: Evusheld (tixagevimab+cilgavimab) IM or IV

Sponsor

MediMergent, LLC